Ru‐Ph Nanozyme‐Based Hydrogels for Tumor Chemodynamic Therapy by Enhancing Enzyme Catalytic Efficiency Through Multiple Pathways
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202403868 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Min Xiao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, Harbin Medical University Cancer Hospital, Harbin, 150081, P. R. China. Hauptthemen laut MEDLINE: Hydrogels, Ruthenium, Nanoparticles, Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Basic and Clinical Cooperative Research and Promotion Program of Anhui Medical University, Natural Science Foundation of Heilongjiang Province.
Abstract (Originalsprache)
The discovery of nanozymes has opened new possibilities for tumor therapy. However, their reliance on the tumor microenvironment and limited catalytic efficiency hinder broader applications. In this study, ruthenium‐phenanthroline nanoparticles (Ru‐Phs) are synthesized by combining ruthenium with phenanthroline and subsequently coloaded with the proton pump inhibitor (PPI) pantoprazole into sodium alginate (ALG) to form a Ru‐Phs‐PPI‐ALG hydrogel for in situ tumor therapy. This hydrogel demonstrates excellent chemodynamic properties, forming a gel within tumor tissues and gradually releasing Ru‐Phs, which generates highly toxic reactive oxygen species (ROS) via peroxidase‐like (POD‐like) activity. The inclusion of PPI reduced the intracellular pH of tumor cells, accelerating the Fenton reaction and ROS accumulation. Additionally, the high photothermal conversion efficiency of Ru‐Phs‐PPI‐ALG enables heat generation under near‐infrared (NIR) irradiation, which not only disrupts tumor cell structures but also further enhances the POD‐like catalytic activity of Ru‐Phs. The hydrogel effectively killed 4T1 cells in vitro, and transcriptomic analysis confirms its potent chemodynamic efficacy. In vivo experiments demonstrate significant tumor ablation and excellent biocompatibility. This multipathway strategy to increase enzyme activity and improve chemodynamic effects provides a promising approach for advancing nanozyme applications in tumor therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgical Oncology, Harbin Medical University Cancer Hospital, Harbin, 150081, P. R. China.
- Department of Orthopedics, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, P. R. China.
- Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230032, P. R. China.
- School of Biomedical Engineering, Research and Engineering Center of Biomedical Materials, Anhui Provincial Institute of Translational Medicine, Anhui Medical University, Hefei, 230032, P. R. China.
ORCID-Profile: Xianwen Wang
Förderung
- National Natural Science Foundation of China
- Basic and Clinical Cooperative Research and Promotion Program of Anhui Medical University
- Natural Science Foundation of Heilongjiang Province
Zitieren
APA
Xiao, M., Zhang, Y., Xing, J., Qiao, K., Ba, Y., Wang, X., Gao, S., & Yuan, Z. (2025). Ru‐Ph Nanozyme‐Based Hydrogels for Tumor Chemodynamic Therapy by Enhancing Enzyme Catalytic Efficiency Through Multiple Pathways. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202403868
Vancouver
Xiao M, Zhang Y, Xing J, Qiao K, Ba Y, Wang X, et al. Ru‐Ph Nanozyme‐Based Hydrogels for Tumor Chemodynamic Therapy by Enhancing Enzyme Catalytic Efficiency Through Multiple Pathways. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202403868
BibTeX
@article{Xiao2025,
author = {Xiao, Min and Zhang, Yiqun and Xing, Jianghao and Qiao, Kun and Ba, Yuling and Wang, Xianwen and Gao, Song and Yuan, Zhennan},
title = {Ru‐Ph Nanozyme‐Based Hydrogels for Tumor Chemodynamic Therapy by Enhancing Enzyme Catalytic Efficiency Through Multiple Pathways},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202403868}
}
EUVIMED